Single-Photon Emission Computed Tomography Tracers in the Diagnostics of Neuroendocrine Tumors - 25/11/13
Doi : 10.1016/j.cpet.2013.08.011
Giovanna Pepe, MD a, Emilio Bombardieri, MD b, Alice Lorenzoni, MD b, Arturo Chiti, MD a, ⁎ 
a Nuclear Medicine Department, Humanitas Clinical and Research Institute, Via A. Manzoni 56, 20089 Rozzano, Milan, Italy
b Nuclear Medicine Department, National Cancer Institute, Via G. venezian 1, Milan 20133, Italy
∗Corresponding author. Humanitas Clinical and Research Institute, Via A. Manzoni 56, 20089 Rozzano, Milan, Italy.
Résumé |
Different imaging strategies have been developed targeting the peculiar features of neuroendocrine tumors (NETs). Metabolic characteristics and receptor expression on the tumor surface have been studied, and expertise and knowledge are increasing as a result of the implementation of fusion imaging and the development of more detailed positron emission tomography tracers. Scintigraphic study of NETs is the most diffused and convenient technique for evaluating patients suspected to have NETs.
Le texte complet de cet article est disponible en PDF.Keywords : mIBG, Somatostatin, Somatostatin analogues, Pentetreotide
Plan
| Conflict of Interest Statement: The authors have no conflict of interest to declare. |
© 2014
Elsevier Inc. Tous droits réservés.
Vol 9 - N° 1
P. 11-26 - janvier 2014 Retour au numéro
Article précédent
- Nuclear Medicine Procedures in the Diagnosis of NET : A Historical Perspective
- Anna Margherita Maffione, Sellam Karunanithi, Rakesh Kumar, Domenico Rubello, Abass Alavi
- 18F-Fluorodihydroxyphenylalanine in the Diagnosis of Neuroendocrine Tumors
- Heikki Minn, Jukka Kemppainen, Saila Kauhanen, Sarita Forsback, Marko Seppänen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?